Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis
ConclusionIn transplant-ineligible patients with NDMM, D-VMP showed superior effectiveness versus bortezomib- and thalidomide-based regimens, supporting adoption of daratumumab-containing regimens in Latin America.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Chronic Kidney Disease | Drugs & Pharmacology | Kidney Transplant | Kidney Transplantation | Myeloma | Prednisone | Study | Transplant Surgery | Transplants | Urology & Nephrology | Velcade